Ventures

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

UltraTIL enables real-time tool-in-lesion confirmation during endobronchial lung cancer biopsies. This compact, side-viewing ultrasound probe is designed for the peripheral airways. UltraTil can be inserted through the working channel of a bronchoscope or robotic platform. By visualising lesions perpendicular to the airway and displaying the needle or biopsy instrument entering the target, UltraTIL improves the identification and sampling of small, eccentric and hard-to-reach lesions. The result: higher diagnostic accuracy, less reliance on additional positioning instruments, and shorter, more efficient procedures.

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

The Venous Stent is a new type of stent designed to help with conditions like deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). Unlike older stents, this one can adjust in length and has multiple parts, making it more flexible and better for the veins. It helps improve blood flow and healing in the veins, potentially reducing the need for long-term medication.

DiaphOne TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. DiaphOne TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

StarTric, created by cardiovascular experts, developed a new, less invasive device to fix a serious heart valve problem, Tricuspid Regurgitation (TR). Addressing Tricuspid Regurgitation (TR), a severe condition with high mortality rates, StarTric's device offers a safer alternative to open-heart surgery. The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique, aiming to provide effective treatment to millions of TR patients worldwide who currently lack suitable options.

Revadix is a pioneering biotech venture focused on transforming the treatment of atrial fibrillation (AF), a common heart rhythm disorder. The company is developing AM-001, a novel therapy that targets the EPAC-1 protein, aiming to restore normal heart rhythm and offer a curative solution rather than just symptom management. Revadix’s approach promises to improve patient outcomes with fewer side effects and better long-term health results. Supported by NLC Health Ventures, the company is advancing AM-001 towards clinical trials, with the potential to revolutionize cardiovascular care.

Lumabs introduces a revolutionary diagnostic platform offering quick and precise biomolecule measurement right at the point of care. By eliminating the need for time-consuming laboratory processes, such as ELISA tests, Lumabs ensures patients receive vital diagnostic results immediately. This innovation is crucial in emergency and intensive care settings, where real-time information can guide rapid treatment decisions, potentially saving lives.